Experimental studies in rodent AP models demonstrate that emodin (10 mg/kg, oral) significantly attenuates pancreatic and lung tissue damage by suppressing ROS activity and downregulating NLRP3 inflammasome components (NLRP3, caspase-1, and IL-18), thereby reducing systemic inflammation (Xia et al., 2019). This evidence concerns the gene CASP1 and alkaline phosphatase measurement.